Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, discusses findings of a new physician survey that the company conducted.

Sentiments Surrounding At-Home Diagnostic Testing

Articles

Why they are a game changer, and ways to a adapt to a new era of state privacy regulations.

How State Privacy Laws Are Shaping DTC and HCP Marketing Strategies 

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform. 

Kite to Assess Cellares’ Automated Manufacturing Platform

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles. 

Solving Challenges Within the Pharma Supply Chain

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility. 


'Maturity' Matters: Fortifying Two Key Cogs of Pharma Supply Chain 

The company's latest service provides risk and quality management for the pharma and healthcare sectors.

Overhaul Launches Software Tailored Toward Temperature-Sensitive Cargo 

By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy. 

Combining RWE and AI to Bend the Adherence Curve 

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora, offers his thoughts on industry pain points and where he envisions the market progressing in terms of its technological capabilities. 

Cencora VP & Head of Cell & Gene Therapy Service Line Discusses Industry Pain Points and Technological Capabilities

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

The Impact of Serialization Technology: Ensuring Product Integrity and Regulatory Compliance

Results from the CORE-001 clinical trial are expected to be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. 

CG Oncology Reveals Promising Results from Phase II CORE-001 Clinical Trial for the Treatment of BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Data & Technology